

Request for Information (RFI)



“Broad Spectrum Prophylactics for Acetylcholinesterase Inhibitors”

Issued by:
Advanced Technology International (ATI),
Medical CBRN Defense Consortium
315 Sigma Drive
Summerville, SC 29486

Request Issue Date: September 11, 2025

Responses Due Date: October 08, 2025
Noon Eastern Time

Purpose:

The Medical CBRN Defense Consortium (MCDC) is pleased to post this announcement for a Request for Information (RFI) on behalf of Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) focused on surveying current industry capabilities in the engineering, testing, and manufacturing of solutions capable of neutralizing a broad spectrum of acetylcholinesterase (AChE) inhibitors before they affect nervous system targets. The information gathered by this RFI will be shared with relevant interested Government parties to help inform future development and procurement efforts. **This is not a solicitation and JPEO-CBRND is not requesting proposals at this time.**

In addition, all submitting parties are requested to participate in an Industry Day for Prophylactic Chemical Medical Countermeasures, to be held virtually on 06 November 2025 (subject to change) followed by in-person one-on-one sessions to occur between 07 and 21 November 2025 in Frederick, MD. The purpose of this Industry Day is to identify industry partners and capabilities to develop prophylactic AChE inhibitor medical countermeasures (MCM) and allow organizations external to the JPEO-CBRND to help ensure the program efforts align with current, enduring, and emerging threats across agencies and services. More information on these upcoming industry days will be provided to interested parties responding to the RFI.

TECHNOLOGY TOPIC AREAS:**Background**

This effort seeks to identify medical technologies and solutions that can be leveraged to provide prophylactic¹ protection against AChE inhibitor exposure to the U. S. Warfighter. The objective is to enable military personnel to maintain functionality in an AChE inhibitor contaminated environment and/or to allow for rapid recovery and return to duty following exposure. The Department of Defense (DoD) is seeking innovative solutions from all potential medical technology or solution providers in support of two Fiscal Year 2027 (FY27) new start programs: Beacon and Prophylactic Technology System (ProTecS).

Beacon

Beacon is a FY27 new start being stood up for the purpose of screening candidates and is seeking prophylactic candidates against AChE inhibitor threats for evaluation. The program will accelerate the identification and screening of AChE inhibitor threat MCM candidates through a data-driven approach. Beacon will streamline the evaluation process with defined performance and programmatic metrics, leveraging modeling and simulation for a decision support tool. Beacon will conduct efficient, short-duration non-clinical testing of MCM candidates. Studies are expected to target operationally relevant parameters, integrated with modeling and simulation, to demonstrate effectiveness in a simulated operational environment. Beacon will establish and

¹ Prophylactic refers to a medical treatment that prevents or significantly reduces the effects of AChE inhibitor exposure with no to minimal therapeutic post-exposure medical countermeasures needed.

maintain a robust pipeline, seamlessly transitioning successful candidates to continued advanced development.

ProTecS

ProTecS is a FY27 new start being stood up to transition candidates identified by Beacon for advanced development. ProTecS aims to enhance warfighter protection against AChE inhibitor threats by expediting the development and fielding of United States Food and Drug Administration (FDA)-approved prophylactics. ProTecS will rapidly develop candidates, utilizing multiple technical decision points to assess maturity and efficiently off-ramp under-performing options. ProTecS will leverage the investment pipeline, Beacon, to identify high-potential candidates and will utilize data to inform decision-making.

Performance Requirements: The Government is seeking informational papers on operationally relevant medical solutions that address **any or all** of the following topic areas:

- **Topic Area 1: Subcontractor Management**

The Government is seeking to identify companies capable of facilitating subcontracts to drug development and test and evaluation performers. Interested parties should indicate their willingness to team with Government-identified drug developers. Qualified companies should have the ability to manage deliverables on multiple subcontracts with experience ensuring on-time deliveries within cost and schedule and ability to quickly award subcontracts. Respondents are encouraged to include any relevant, past, teaming experiences from similar efforts.

- **Topic Area 2: Prophylactic Candidates**

The Government is seeking candidates that provide prophylactic protection against AChE inhibitor exposure that minimally impact performance post-administration and maintain functionality of military personnel in an AChE inhibitor contaminated environment and/or allow affected personnel to survive and rapidly return to duty.

Optimal prophylactic medical technology(ies) or solution(s) would include the following:

- Safe for use by healthy (unexposed individuals) with minimal impact to physical or mental performance.
- Capability to protect the Warfighter against the broadest number of AChE inhibitor types feasible.
- Capability to maintain effective protection ratios, minimizing the need for repeated dosing.
- Capability to be safely administered with other common medications.
- Capability to obtain FDA authorization and/or approval.
- Demonstrated manufacturability and a robust, reliable supply chain without prohibitive cost.

- Capability to be stored and administered in a combat environment.
- **Topic Area 3: Candidate Testing and Evaluation**
The Government is seeking to identify companies capable of testing candidates for medical and operational relevance and companies capable of advanced development of candidates through FDA licensure.
 - Methods for correlating study results to maintenance of force metrics.
 - Methods to measure operational relevance of candidates.
 - Non-clinical and clinical testing of candidates.
 - Candidate manufacturing capabilities.
 - Strategies for obtaining FDA licensure for prophylactic solutions.

Out of Scope Solutions:

Solutions that do not prevent functional degradation following AChE inhibitor exposure will not be considered.

Administration:

The intent of this RFI is to understand MCDC member interest and technology capabilities within the above-mentioned focus area. Responses will be shared with the Government.

Responses may be submitted at any time during the submission period but no later than the due date and time specified on the first page of this RFI. Offerors are to submit:

1. A two-page written response (template provided in **Addendum 1 of this RFI**)

Responses must be sent to mcdc@ati.org with the subject line denoting the Responding organization and RFI Title. Offerors should use the template provided in **Addendum 1 of this RFI** as a guide as they develop their submission. Material that is advertisement-only in nature is not desired.

MCDC membership is NOT required for the submission to this RFI. However, should this RFI result in a formal solicitation through the MCDC Consortium, membership will be required for submission of an Enhanced White Paper.

Note: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. Request for Information papers should NOT include proprietary or classified information.

MCDC:

MCDC is a medical CBRN Defense consortium collaborating with multiple government agencies under a 20-year Other Transaction Agreement (OTA), with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND). MCDC is currently recruiting a broad and diverse membership that includes representatives from large businesses, small businesses, “non-traditional” government contractors, academic research institutions and not-for-profit organizations with collective expertise in the technology areas specifically related to medical countermeasures.

POINTS OF CONTACT:

For inquiries, please direct your correspondence to the following contacts:

- Government Technical questions should be directed to Ms. Amy Sands, amy.l.sands4.civ@army.mil
- ATI Technical questions should be directed to the Biomedical Technology Liaison, Dr. Chuck Hutti, Ph.D., chuck.hutti@ati.org
- All other questions should be directed to the MCDC Program Manager, Mr. Robert Harwell, mcdc@ati.org

Addendum 1 - MCDC Project Information Template:

[2-page limit. Times New Roman 11 point (or larger), Single-spaced, single-sided, 8.5 inches x 11 inches). Smaller type may be used in figures and tables, but must be clearly legible. Margins on all sides (top, bottom, left, and right) should be at least 0.5 inch. References are excluded from the page limit. These project information submissions will be shared with the Government; therefore, all information must be **nonproprietary**. Project Information Paper should be submitted as a Word (*.doc or *.docx) document using the template provided in this RFI.]

Date: [Insert date of submission]

Title: [Insert descriptive title of project]

Point of Contact: [Insert name, organization, email address, phone number]

Topic Area(s): [Indicate any and all topic areas relevant to this Information Paper]

General Prior Experience: [Describe your general experience as it relates to developing, obtaining regulatory clearance, and manufacturing prophylactics, especially those targeting AChE inhibitors.]

Specific Prior Experience: [Describe your experience/expertise relevant to this specific area of interest, including but not limited to:

- Non-clinical studies and analytical assays for similar solution development
- Clinical studies for similar solution development
- Regulatory strategy, plan and execution to obtain regulatory clearance for similar solutions
- Provide any case studies or references for similar projects for which your company has participated.]

Proposed Solution: [Describe how the proposed solution will meet the above-mentioned requirements. Include information on:

- The scientific rationale for the project, including a brief description of the previous studies or preliminary data that support both the feasibility of proposed work and the indicated Technology Readiness Level (TRL); Please reference the [TRL definitions](#) for further information regarding expected scope of work for advancement toward the next TRL
- Describe relevant non-clinical data and/or clinical preliminary data
- Describe your demonstration of the manufacturing feasibility of the solution
- Proposed indication
- Proposed regulatory strategy
- Route of administration and dosage form

- Protection duration
- Mechanism of action
- Estimated cost per dose
- Storage considerations and/or cold chain requirements
- Product development stage

Respondents should indicate any capabilities that allow their solution to meet the optimal requirements listed within this RFI.]

Industry Day RSVP: [Please indicate your availability on 06 November 2025 for a virtual industry day. Include:

- The names and contact information for expected attendees from your organization
- Your team's availability for an in-person one-on-one session with the Government between 07 and 21 November 2025 in Frederick, MD
 - Note: slide presentations on your solution are expected during the in-person sessions]

Acknowledgement of Willingness to allow the Government and the MCDC CM access to your Information Paper for the purposes of engaging in market landscape activities with private sector entities: **Indicate YES or NO** [The Government wishes to use the responses provided from this effort to bolster ongoing market landscape activities.]